Literature DB >> 22965529

Dual-bioactivity-based liquid chromatography-coupled quadrupole time-of-flight mass spectrometry for NF-κB inhibitors and β2AR agonists identification in Chinese Medicinal Preparation Qingfei Xiaoyan Wan.

Binfeng Cheng1, Yuanyuan Hou, Liqiang Wang, Linyi Dong, Jiamin Peng, Gang Bai.   

Abstract

Traditional Chinese medicine (TCM) preparations have been used as an effective multitarget strategy for the treatment of complex diseases; however, their bioactive constituents are undefined and difficult to identify. In this study, a simple and dual-target method based on ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry combined with dual-bioactive (NF-κB and β(2)-adrenergic receptor) luciferase reporter assay systems was developed for the rapid determination of various bioactive compounds of TCM preparations. Qingfei Xiaoyan Wan, a TCM preparation used for the clinical therapy of asthma, was analyzed with this method. Potential anti-inflammatory and spasmolytic constituents were screened using NF-κB and β(2)-adrenergic receptor activity luciferase reporter assay systems and simultaneously identified according to the time-of-flight mass spectrometry data. One β(2)-adrenergic receptor agonist (ephedrine) and four structural types of NF-κB inhibitors (arctigenin derivatives, cholic acid derivatives, chlorogenic acid, and sinapic acid) were characterized. Tracheloside was considered a new NF-κB inhibitor. Further cytokine and chemokine detection confirmed the anti-inflammatory effects of the potential NF-κB inhibitors. The integration of ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry and dual-bioactive human cell functional evaluation systems proved to be a simple and effective strategy for the rapid screening of various bioactive compounds in TCM preparations used to treat complex diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22965529     DOI: 10.1007/s00216-012-6332-9

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  8 in total

1.  Identification and comparison of anti-inflammatory ingredients from different organs of Lotus nelumbo by UPLC/Q-TOF and PCA coupled with a NF-κB reporter gene assay.

Authors:  Mengge Zhou; Min Jiang; Xuhui Ying; Qingxin Cui; Yanqi Han; Yuanyuan Hou; Jie Gao; Gang Bai; Guoan Luo
Journal:  PLoS One       Date:  2013-11-29       Impact factor: 3.240

2.  Searching for synergistic bronchodilators and novel therapeutic regimens for chronic lung diseases from a traditional Chinese medicine, Qingfei Xiaoyan Wan.

Authors:  Yuanyuan Hou; Binfeng Cheng; Mengge Zhou; Runping Fang; Min Jiang; Wenbin Hou; Gang Bai
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

3.  Identification of nuclear factor-κB inhibitors in the folk herb Rhizoma Menispermi via bioactivity-based ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry analysis.

Authors:  Dan Sun; Mengge Zhou; Xuhui Ying; Binfeng Cheng; Yanqi Han; Yan Nie; Yuanyuan Hou; Gang Bai
Journal:  BMC Complement Altern Med       Date:  2014-09-25       Impact factor: 3.659

4.  Qingfei Xiaoyan Wan, a traditional Chinese medicine formula, ameliorates Pseudomonas aeruginosa-induced acute lung inflammation by regulation of PI3K/AKT and Ras/MAPK pathways.

Authors:  Yuanyuan Hou; Yan Nie; Binfeng Cheng; Jin Tao; Xiaoyao Ma; Min Jiang; Jie Gao; Gang Bai
Journal:  Acta Pharm Sin B       Date:  2016-03-22       Impact factor: 11.413

5.  Systematic identification of the interventional mechanism of Qingfei Xiaoyan Wan (QFXYW) in treatment of the cytokine storm in acute lung injury using transcriptomics-based system pharmacological analyses.

Authors:  Jing-Yi Hou; Jia-Rong Wu; Yi-Bing Chen; Dong Xu; Shu Liu; Dan-Dan Shang; Guan-Wei Fan; Yuan-Lu Cui
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.503

6.  Qingfei Xiaoyan Wan alleviates asthma through multi-target network regulation.

Authors:  Zhenying Zhao; Yingbo Miao; Pengwei Pan; Binfeng Cheng; Gang Bai; Hong Wu
Journal:  BMC Complement Altern Med       Date:  2013-08-06       Impact factor: 3.659

7.  Sinapic Acid Derivatives as Potential Anti-Inflammatory Agents: Synthesis and Biological Evaluation.

Authors:  Qiongyu Zhang; Jun-Xiao Hu; Xu Kui; Chao Liu; Hui Zhou; Xiaoxin Jiang; Leping Zeng
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

8.  Combining UPLC/Q-TOF-MS/MS With Biological Evaluation for NF-κB Inhibitors in Uyghur Medicine Althaea rosea Flowers.

Authors:  Fang Ma; Qingxin Cui; Gang Bai
Journal:  Front Plant Sci       Date:  2019-01-09       Impact factor: 5.753

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.